159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. (December 2022)

Record Type:
Journal Article
Title:
159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer. (December 2022)
Main Title:
159P COM701 in combination with nivolumab demonstrates preliminary antitumor activity in patients with platinum-resistant epithelial ovarian cancer
Authors:
Yeku, O.
D. Shepard,
Patel, M.
Fleming, G.
Vaena, D.
Rasco, D.
Chmielowski, B.
Sharma, M.R.
Hamilton, E.
Sullivan, R.J.
Papadopoulos, K.
Izar, B.
Cojocaru, G.
Ophir, E.
Ferre, P.J.
Dumbrava, E.E.
Abstract:
Is Part Of:
Immuno-oncology technology. Volume 16(2022)Supplement 1
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Issue Display:
Volume 16, Issue 1 (2022)
Year:
2022
Volume:
16
Issue:
1
Issue Sort Value:
2022-0016-0001-0000
Page Start:
Page End:
Publication Date:
2022-12
Subjects:
Cancer -- Immunotherapy -- Periodicals
616.994061
Journal URLs:
https://www.esmoiotech.org/issues ↗
http://www.sciencedirect.com/ ↗
DOI:
10.1016/j.iotech.2022.100271 ↗
Languages:
English
ISSNs:
2590-0188
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store
Ingest File:
24744.xml